文献速递神经免疫神经肌肉病

CRMP5自身免疫性神经病:105例表型与结局分析

Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases.
PubMed 文献 · Neurology · 2017-12-08

本研究基于105例CRMP5-IgG神经病患者与51例ANNA1-IgG神经病患者的对比,确立CRMP5神经病以疼痛性非对称性轴索性多神经根神经病为主要表型,常先于癌症诊断出现,免疫治疗可显著缓解疼痛并改善神经功能评分。

要点

  • CRMP5神经病典型表现为疼痛性非对称性轴索性多神经根神经病,多数患者有吸烟史且合并癌症。
  • 该表型疼痛 prevalence 高,脑脊液炎症常见,且神经病症状常早于癌症诊断约185天出现。
  • 免疫治疗尤其是大剂量皮质类固醇与神经功能改善/稳定相关,且CRMP5患者5年生存率优于ANNA1患者。

核心结论

  • CRMP5自身免疫性神经病以疼痛性非对称性轴索性多神经根神经病为主要表现,可与ANNA1等其他副肿瘤性神经病区分。
  • 具有该表型的患者应进行CRMP5-IgG检测以辅助早期癌症诊断。

研究设计与样本

  • 回顾性队列研究,纳入105例CRMP5-IgG神经病患者,并与51例ANNA1-IgG神经病患者(其中27例共存CRMP5-IgG)进行比较。

主要发现

  • 105例CRMP5-IgG神经病患者中88%为吸烟者,69%合并癌症,最常见为小细胞肺癌(75%)。
  • CRMP5神经病表现为疼痛性轴索性多神经根神经病(65%),84%为非对称起病,神经病症状早于癌症诊断185天(范围60-540天)。
  • 79%的CRMP5患者有中度至重度神经病理性疼痛,均使用神经病理性疼痛药物(中位数2种,范围1-4),39%使用阿片类药物。
  • 与单纯ANNA1相比,CRMP5神经病疼痛患病率更高(79% vs 46%,p=0.008),非对称性多神经根神经病更常见(54% vs 12%,p<0.001),脑脊液炎症比例更高(92% vs 60%,p=0.022)。
  • 常见伴随神经系统表现包括小脑性共济失调(21%)、脊髓病(19%)、视神经炎和/或视网膜炎(11%)。

关键数值与推荐

  • CRMP5神经病诊断需结合临床表型(疼痛性非对称性轴索性多神经根神经病)及CRMP5-IgG检测。
  • 神经活检(n=2)显示微血管炎症伴轴索变性。

临床怎么用

  • 对表现为疼痛性非对称性多神经根神经病的患者,应检测CRMP5-IgG以协助早期发现潜在癌症。
  • 免疫治疗(包括大剂量皮质类固醇)可考虑用于改善神经功能评分和减轻疼痛。

局限性

  • 回顾性研究设计,证据等级有限(部分分析为Class IV)。
  • 神经活检样本量小(n=2)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To establish the phenotype and clinical outcomes of collapsin response-mediator protein-5 (CRMP5) autoimmune neuropathy in comparison with anti-neuronal nuclear antibody type 1 (ANNA1)-immunoglobulin G (IgG) neuropathy. METHODS: Patients with CRMP5-IgG and/or ANNA1-IgGs were identified in our service-line testing, and medical records were reviewed. RESULTS: One hundred five patients with CRMP5-IgG neuropathy (88% smokers; 69% having cancer, most commonly small cell lung cancer [75%]) were identified and compared to 51 patients with ANNA1-IgG neuropathy, 27 with coexisting CRMP5-IgG. Patients with CRMP5 had painful axonal polyradiculoneuropathy (65%), mostly asymmetric onset (84%), with neuropathy predating cancer diagnosis by 185 days (range 60-540 days). Most cases (79%) had moderate to severe neuropathic pain, all on neuropathic medications (median 2, range 1-4), opioids in 39%. Nerve biopsies (n = 2) showed microvascular inflammation with axonal degeneration. Compared to ANNA1 alone, CRMP5 neuropathy has a higher prevalence of pain (79% vs 46%, p = 0.008), asymmetric polyradiculoneuropathy (54% vs 12%, p < 0.001), and inflammatory spinal fluids (elevated CSF protein or nucleated cell count 92% vs 60%, p = 0.022). Cerebellar ataxia (21%), myelopathy (19%), and optic neuritis and/or retinitis (11%) were common neurologic accompaniments. CRMP5 cases had significant pain reduction by immunotherapy (p < 0.001). Specifically, high-dose corticosteroid administration was associated with improvement/stabilization in neuropathy impairment scores (p = 0.012) (Class IV). Patients with CRMP5 had better 5-year survival than patients with ANNA1 (67% vs 32%, p = 0.012). CONCLUSION: Painful axonal asymmetric polyradiculoneuropathy is established as the major CRMP5 autoimmune neuropathy presentation and is distinguishable from other paraneoplastic neuropathies, including by ANNA1 autoimmunity. Patients with this phenotype should be prompted for CRMP5-IgG testing to assist in early cancer diagnosis.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Dubey D, Lennon VA, Gadoth A, et al. Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. Neurology. 2017. PMID: 29222126. doi:10.1212/WNL.0000000000004803

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。